A J M van den Eertwegh

Summary

Affiliation: VU University Medical Center
Country: The Netherlands

Publications

  1. ncbi request reprint Active specific immunotherapy in colon cancer
    A J M van den Eertwegh
    Department of Medical Oncology, Vrije Universiteit Medical Center, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands
    Recent Results Cancer Res 165:260-7. 2005
  2. pmc A phase II study of active specific immunotherapy and 5-FU/Leucovorin as adjuvant therapy for stage III colon carcinoma
    A Baars
    Department of Medical Oncology, Vrije Universiteit Medical Center, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands
    Br J Cancer 86:1230-4. 2002
  3. pmc IL-21 promotes the expansion of CD27+ CD28+ tumor infiltrating lymphocytes with high cytotoxic potential and low collateral expansion of regulatory T cells
    Saskia J A M Santegoets
    Department of Medical Oncology, VU University Medical Center, Amsterdam, The Netherlands
    J Transl Med 11:37. 2013
  4. pmc Health related quality of life outcomes for unresectable stage III or IV melanoma patients receiving ipilimumab treatment
    Dennis A Revicki
    United BioSource Corporation, Bethesda, MD 20814, USA
    Health Qual Life Outcomes 10:66. 2012
  5. doi request reprint Safety of everolimus by treatment duration in patients with advanced renal cell cancer in an expanded access program
    Alfonsus J M van den Eertwegh
    VU University Medical Center, Amsterdam, The Netherlands
    Urology 81:143-9. 2013
  6. pmc Phase I-II study of everolimus and low-dose oral cyclophosphamide in patients with metastatic renal cell cancer
    Charlotte M Huijts
    Department of Medical Oncology, VU University Medical Center, Amsterdam, The Netherlands
    BMC Cancer 11:505. 2011
  7. ncbi request reprint Adjuvant treatment of colorectal cancer: towards tumor-specific immunotherapies
    A J van den Eertwegh
    Division of Immunotherapy, Vrije Universiteit Medical Center, Amsterdam, The Netherlands
    Cancer Metastasis Rev 20:101-8. 2001
  8. pmc Choi response criteria for early prediction of clinical outcome in patients with metastatic renal cell cancer treated with sunitinib
    A A M van der Veldt
    Department of Medical Oncology, VU University Medical Center, De Boelelaan 1117, Amsterdam, The Netherlands
    Br J Cancer 102:803-9. 2010
  9. pmc Predictive factors for severe toxicity of sunitinib in unselected patients with advanced renal cell cancer
    A A M van der Veldt
    Department of Medical Oncology, VU University Medical Center, Amsterdam, The Netherlands
    Br J Cancer 99:259-65. 2008
  10. ncbi request reprint Melanoma-specific tumor-infiltrating lymphocytes but not circulating melanoma-specific T cells may predict survival in resected advanced-stage melanoma patients
    J B A G Haanen
    Division of Immunology, Netherlands Cancer Institute, Plesmanlaan 121, 1066, Amsterdam, The Netherlands
    Cancer Immunol Immunother 55:451-8. 2006

Collaborators

  • R J Scheper
  • E Boven
  • S Meijer
  • G Giaccone
  • Herbert M Pinedo
  • J B Vermorken
  • Amit Bahl
  • A Baars
  • Yen Chuan Ou
  • Sergio Bracarda
  • C J L M Meijer
  • K Hoekman
  • E Bloemena
  • J A Gietema
  • Bart C Kuenen
  • A A M van der Veldt
  • J B A G Haanen
  • T D de Gruijl
  • Saskia J A M Santegoets
  • Tanja D de Gruijl
  • Dennis A Revicki
  • Charlotte M Huijts
  • B J R Sluijter
  • A G M Stam
  • P H M de Mulder
  • H van Cruijsen
  • Erik Hooijberg
  • Winald R Gerritsen
  • Daniel J Powell
  • Steve M Albelda
  • Annelies W Turksma
  • Anita G M Stam
  • Megan M Suhoski
  • Carl H June
  • Axel Hoos
  • Paul Lorigan
  • Celeste Lebbe
  • Christian H Ottensmeier
  • Marianne Messina
  • Shima Safikhani
  • Srividya Kotapati
  • Gerald Linette
  • Samuel Wagner
  • Saskia J Santegoets
  • Hans J van der Vliet
  • John B Haanen
  • Laura S Pijpers
  • Henk M Verheul
  • S J A M Santegoets
  • S M Lougheed
  • P A M van Leeuwen
  • M P van den Tol
  • M R Meijerink
  • C H June
  • M M Suhoski
  • M F C M van den Hout
  • M van Wouwe
  • W H J Kruit
  • P F A Mulders
  • E E Voest
  • H Mallo
  • G de Gast
  • S Sleijfer
  • G Groenewegen
  • C N Tillier
  • J Berkhof
  • D J Richel
  • H H Helgason
  • S Osanto
  • R L H Jansen
  • B M E von Blomberg
  • P Weder
  • R Gomez
  • M Smits
  • S M van Ham

Detail Information

Publications15

  1. ncbi request reprint Active specific immunotherapy in colon cancer
    A J M van den Eertwegh
    Department of Medical Oncology, Vrije Universiteit Medical Center, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands
    Recent Results Cancer Res 165:260-7. 2005
    ..A randomized phase III trial is now warranted to show that the combination of ASI and chemotherapy is superior to chemotherapy alone...
  2. pmc A phase II study of active specific immunotherapy and 5-FU/Leucovorin as adjuvant therapy for stage III colon carcinoma
    A Baars
    Department of Medical Oncology, Vrije Universiteit Medical Center, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands
    Br J Cancer 86:1230-4. 2002
    ....
  3. pmc IL-21 promotes the expansion of CD27+ CD28+ tumor infiltrating lymphocytes with high cytotoxic potential and low collateral expansion of regulatory T cells
    Saskia J A M Santegoets
    Department of Medical Oncology, VU University Medical Center, Amsterdam, The Netherlands
    J Transl Med 11:37. 2013
    ..Here, we have compared the effects of IL-2, -15 and -21 cytokines on the expansion and activation of TIL from single-cell suspensions of non-small cell lung cancer, ovarian cancer and melanoma...
  4. pmc Health related quality of life outcomes for unresectable stage III or IV melanoma patients receiving ipilimumab treatment
    Dennis A Revicki
    United BioSource Corporation, Bethesda, MD 20814, USA
    Health Qual Life Outcomes 10:66. 2012
    ..This report summarizes health-related quality of life (HRQL) outcomes for ipilimumab with/without gp100 vaccine compared to gp100 alone during the clinical trial's 12 week treatment induction period...
  5. doi request reprint Safety of everolimus by treatment duration in patients with advanced renal cell cancer in an expanded access program
    Alfonsus J M van den Eertwegh
    VU University Medical Center, Amsterdam, The Netherlands
    Urology 81:143-9. 2013
    ..To retrospectively analyze the effects of treatment duration on outcomes of everolimus treatment of patients in the RAD001 Expanded-Access Clinical Trial in RCC (REACT) program...
  6. pmc Phase I-II study of everolimus and low-dose oral cyclophosphamide in patients with metastatic renal cell cancer
    Charlotte M Huijts
    Department of Medical Oncology, VU University Medical Center, Amsterdam, The Netherlands
    BMC Cancer 11:505. 2011
    ..This study intends to investigate whether the antitumor efficacy of everolimus can be increased by preventing the detrimental everolimus induced expansion of Tregs using a metronomic schedule of cyclophosphamide...
  7. ncbi request reprint Adjuvant treatment of colorectal cancer: towards tumor-specific immunotherapies
    A J van den Eertwegh
    Division of Immunotherapy, Vrije Universiteit Medical Center, Amsterdam, The Netherlands
    Cancer Metastasis Rev 20:101-8. 2001
    ..Phase II/III clinical trials investigating these different modalities in colorectal cancer are reviewed...
  8. pmc Choi response criteria for early prediction of clinical outcome in patients with metastatic renal cell cancer treated with sunitinib
    A A M van der Veldt
    Department of Medical Oncology, VU University Medical Center, De Boelelaan 1117, Amsterdam, The Netherlands
    Br J Cancer 102:803-9. 2010
    ..Because sunitinib can induce extensive necrosis in metastatic renal cell cancer (mRCC), we examined whether criteria defined by Choi might be valuable to predict early sunitinib efficacy...
  9. pmc Predictive factors for severe toxicity of sunitinib in unselected patients with advanced renal cell cancer
    A A M van der Veldt
    Department of Medical Oncology, VU University Medical Center, Amsterdam, The Netherlands
    Br J Cancer 99:259-65. 2008
    ..On the basis of age and gender, a model was developed that could predict the probability of severe toxicity...
  10. ncbi request reprint Melanoma-specific tumor-infiltrating lymphocytes but not circulating melanoma-specific T cells may predict survival in resected advanced-stage melanoma patients
    J B A G Haanen
    Division of Immunology, Netherlands Cancer Institute, Plesmanlaan 121, 1066, Amsterdam, The Netherlands
    Cancer Immunol Immunother 55:451-8. 2006
    ..To investigate the correlation between the presence of tumor-infiltrating lymphocytes (TIL) and circulating TAA-specific CD8+ T cells before and after autologous tumor cell vaccination with overall survival...
  11. doi request reprint 4-1BB-mediated expansion affords superior detection of in vivo primed effector memory CD8+ T cells from melanoma sentinel lymph nodes
    B J R Sluijter
    Department of Surgical Oncology, VU University Medical Center, Cancer Center Amsterdam, Amsterdam, The Netherlands
    Clin Immunol 137:221-33. 2010
    ....
  12. pmc Defective differentiation of myeloid and plasmacytoid dendritic cells in advanced cancer patients is not normalized by tyrosine kinase inhibition of the vascular endothelial growth factor receptor
    H van Cruijsen
    Department of Medical Oncology, VU University Medical Center, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands
    Clin Dev Immunol 2007:17315. 2007
    ..In conclusion, TK inhibition of VEGFR with AZD2171 does not restore the defective PBDC differentiation observed in advanced cancer patients...
  13. ncbi request reprint Metastasectomy and active specific immunotherapy for a large single melanoma metastasis
    A Baars
    Department of Medical Oncology, Vrije Universiteit Medical Center, Amsterdam, The Netherlands
    Hepatogastroenterology 49:691-3. 2002
    ..The role of surgery and immunotherapy in the treatment of metastatic melanoma are discussed...
  14. ncbi request reprint [Adverse effects of the tyrosine-kinase inhibitor sunitinib, a new drug for the treatment of advanced renal-cell cancer]
    A A M van der Veldt
    VU Medisch Centrum, Afd Geneeskundige Oncologie, De Boelelaan 1117, 1081 HV Amsterdam
    Ned Tijdschr Geneeskd 151:1142-7. 2007
    ..It can induce adverse events that differ from those observed in treatment with conventional cytotoxic agents. The adverse effects are reduced by lowering the dosage and in the rest period within the treatment cycle...
  15. ncbi request reprint [Angiogenesis inhibitors for the systemic treatment of metastatic renal cell carcinoma: sunitinib, sorafenib, bevacizumab and temsirolimus]
    P H M de Mulder
    Universitair Medisch Centrum St Radboud, Nijmegen
    Ned Tijdschr Geneeskd 152:371-5. 2008
    ..These angiogenesis inhibitors did not receive mention in the recently published guideline 'Renal cell carcinoma'...